Rare Inflammatory Disease Treatment Market: Trends, Share, Size, In-Depth Analysis Forecast To 2033

The new report published by The Business Research Company, titled Rare Inflammatory Disease Treatment Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033, delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the rare inflammatory disease treatment market size has grown strongly in recent years. It will grow from $13.04 billion in 2023 to $13.82 billion in 2024 at a compound annual growth rate (CAGR) of 6%. The rare inflammatory disease treatment market size is expected to see strong growth in the next few years. It will grow to $17.56 billion in 2028 at a compound annual growth rate (CAGR) of 6.2%.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=15656&type=smp

Rising Autoimmune Conditions Fuel Rare Inflammatory Disease Treatment Market
The increasing prevalence of autoimmune is expected to propel the rare inflammatory disease treatment market going forward. Autoimmune diseases refer to the immune system attacking healthy cells and tissues, resulting in inflammation and tissue damage. The rise of autoimmune diseases is due to genetic predisposition, environmental triggers, lifestyle changes, and improved diagnostic methods, which lead to better detection and recognition of these conditions. Rare inflammatory disease treatments are often utilized to reduce inflammation and prevent the immune system from attacking healthy tissues for patients with autoimmune conditions. For instance, in February 2021, according to the International Osteoporosis Foundation (IOF), a Switzerland-based government organization, more than 300 million people worldwide suffered from rare diseases, affecting 3.5% to 5.9% of the world's population. Furthermore, in November 2022, according to Health Match, an Australia-based digital health company, there are around 150 rare kidney ailments, and these diseases have a high prevalence around the world, with 60-80 incidences per 100,000 people in America and Europe. Therefore, the increasing prevalence of autoimmune is driving the growth of the rare inflammatory disease treatment market.

Precision Medicines For Rare Inflammatory Disease Treatments
Major companies operating in rare inflammatory disease treatments are focused on developing advanced precision medicines such as monoclonal antibodies, to target a specific part of the immune system and gain a competitive edge in the market. Monoclonal antibodies are a critical therapeutic modality in rare inflammatory disease treatments, targeting particular pathways to alleviate symptoms and improve outcomes. For instance, in January 2022, Boehringer Ingelheim, a Germany-based pharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for SPEVIGO. This monoclonal antibody blocks the signaling of interleukin-36 (IL-36). It is the first and only approved medication for treating GPP in adults and adolescents aged 12 years and older, weighing at least 88 pounds (40 kg). SPEVIGO is a targeted treatment that works to help inhibit the activity of the interleukin-36 receptor (IL-36R), a vital part of a signaling pathway within the immune system involved in generalized pustular psoriasis flares.

The rare inflammatory disease treatment market covered in this report is segmented -

1) By Drug Class: Biologics, Organic Compounds
2) By Mode Of Administration: Injectables, Oral, Other Administration Modes
3) By Indication: Ulcerative Colitis, Juvenile Rheumatoid Arthritis, Psoriatic Arthritis, Other Indications
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Buy Now & Get Exclusive Discount on this Report, Checkout link @ https://www.thebusinessresearchcompany.com/Discount?id=15656&type=discount

Major companies operating in the rare inflammatory disease treatment market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co., Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Bristol Myers Squibb, AstraZeneca Plc, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Gilead Sciences, Inc., Amgen Inc., Regeneron Pharmaceuticals, Inc., Biogen Inc., UCB S.A., Jazz Pharmaceuticals plc, Horizon Therapeutics plc, Kyowa Kirin Co., Ltd., BioMarin Pharmaceutical Inc., Mallinckrodt Pharmaceuticals, Sarepta Therapeutics, Inc., Cytokinetics, Incorporated, Orchard Therapeutics plc

Contents of the report:
1. Executive Summary
2. Rare Inflammatory Disease Treatment Market Report Structure
3. Rare Inflammatory Disease Treatment Market Trends And Strategies
4. Rare Inflammatory Disease Treatment Market - Macro Economic Scenario
5. Rare Inflammatory Disease Treatment Market Size And Growth
…..
27. Rare Inflammatory Disease Treatment Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/rare-inflammatory-disease-treatment-global-market-report

Contact us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Latest Trending Press Releases: https://www.thebusinessresearchcompany.com/press-release.aspx

Learn More About The Business Research Company

The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.